The gene-editing drug developer has completed its first publicly announced round to advance UC and ETH Zürich research.

Spotlight Therapeutics, a US-based gene therapy developer advancing University of California (UC) and ETH Zürich research, has raised $30m in a series A round led by GV, a corporate venturing subsidiary of conglomerate Alphabet. The corporate was joined by undisclosed other investors, the round coming in the wake of $7.3m in equity funding in January…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.